BioNTech SE (NASDAQ:BNTX) Shares Purchased by Jones Financial Companies Lllp

Jones Financial Companies Lllp increased its position in shares of BioNTech SE (NASDAQ:BNTX) by 110.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 469 shares of the company’s stock after acquiring an additional 246 shares during the quarter. Jones Financial Companies Lllp’s holdings in BioNTech were worth $53,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in BioNTech by 48.2% during the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock worth $105,000 after purchasing an additional 300 shares during the period. AlphaCentric Advisors LLC purchased a new position in BioNTech during the fourth quarter worth approximately $168,000. SVB Wealth LLC purchased a new position in BioNTech during the fourth quarter worth approximately $204,000. Harbor Advisors LLC purchased a new position in BioNTech during the third quarter worth approximately $238,000. Finally, Freedom Investment Management Inc. purchased a new position in BioNTech during the third quarter worth approximately $243,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on BNTX. Citigroup began coverage on shares of BioNTech in a research note on Thursday, March 13th. They set a “buy” rating and a $145.00 price target on the stock. Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $110.00 to $125.00 in a research note on Tuesday, November 19th. HC Wainwright reaffirmed a “buy” rating and set a $150.00 price target on shares of BioNTech in a research note on Monday, November 18th. Canaccord Genuity Group reissued a “buy” rating and issued a $171.44 target price on shares of BioNTech in a research note on Tuesday, March 11th. Finally, Truist Financial started coverage on shares of BioNTech in a research note on Friday, January 10th. They issued a “buy” rating and a $172.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, BioNTech currently has an average rating of “Moderate Buy” and an average price target of $143.73.

BioNTech Stock Performance

BioNTech stock opened at $100.86 on Tuesday. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a market capitalization of $24.18 billion, a price-to-earnings ratio of -48.03 and a beta of 0.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The firm’s fifty day moving average price is $115.11 and its 200 day moving average price is $113.46.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.70. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm’s quarterly revenue was down 19.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.90 EPS. On average, research analysts forecast that BioNTech SE will post -3.88 EPS for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.